Compare LW & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LW | CNTA |
|---|---|---|
| Founded | 1950 | 2020 |
| Country | United States | United Kingdom |
| Employees | 10100 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.1B |
| IPO Year | 2016 | 2021 |
| Metric | LW | CNTA |
|---|---|---|
| Price | $44.73 | $40.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $44.14 | $43.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 04-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ 1.29 | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.62 | $12.78 |
| 52 Week High | $67.07 | $40.26 |
| Indicator | LW | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 58.50 | 69.06 |
| Support Level | $39.96 | $39.58 |
| Resistance Level | $46.61 | $40.26 |
| Average True Range (ATR) | 1.12 | 0.18 |
| MACD | 0.22 | -0.06 |
| Stochastic Oscillator | 80.46 | 85.71 |
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.